Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro

Tumori

Volumn 97, Issue 6, 2011, Pages 781-786

  Li, Rongrui ^a,b   Wang, Riguang ^b   Zhai, Raosheng ^b   Dong, Zhen ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^b JIAMUSI UNIVERSITY   (China)

Author keywords

Apoptosis; Laryngeal carcinoma; mTOR

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RNAI READY PSIREN RETROQ RETROVIRAL VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CELL ASSAY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARYNX CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VECTOR; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LARYNGEAL NEOPLASMS; MOLECULAR TARGETED THERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84863129098     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1018.11096     Document Type: Article

References (40)

1. Sun G, Wang Y, Zhu Y, Huang C, Ji Q: Duffy antigen receptor for chemokines in laryngeal squamous cell carcinoma as a negative regulator. Acta Otolaryngol, 131: 197-203, 2011.
2. Mnejja M, Hammami B, Bougacha L, Chakroun A, Charfeddine I, Khabir A, Boudaoura T, Ghorbel A: Occult lymph node metastasis in laryngeal squamous cell carcinoma: therapeutic and prognostic impact. Eur Ann Otorhinolaryngol Head Neck Dis, 127: 173-176, 2010.
3. Amar A, Chedid HM, Franzi SA, Rapoport A: Diagnostic and therapeutic delay in patients with larynx cancer at a reference public hospital. Braz J Otorhinolaryngol, 76: 700- 703, 2010.
4. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, Le Maître A, Bernier J, Horiot JC, Maillard E, Pajak TF, Poulsen MG, Bourredjem A, O'Sullivan B, Dobrowsky W, Andrzej H, Skladowski K, Hay JH, Pinto LH, Fu KK, Fallai C, Sylvester R, Pignon JP: MARCH Collaborative Group: Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev, CD002026, 2010.
5. Milisavljevic D, Stankovic M, Zivic M, Popovic M, Radovanovi Z: Factors affecting results of treatment of hypopharyngeal carcinoma. Hippokratia, 13: 154-160, 2009.
6. Reizenstein JA, Bergström SN, Holmberg L, Linder A, Ekman S, Blomquist E, Lödén B, Holmqvist M, Hellström K, Nilsson CO, Brattström D, Bergqvist M: Impact of age at diagnosis on prognosis and treatment in laryngeal cancer. Head Neck, 32: 1062-1068, 2010.
7. Semrau S, Waldfahrer F, Lell M, Linke R, Klautke G, Kuwert T, Uder M, Iro H, Fietkau R: Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early results. Strahlenther Onkol, 187: 15-22, 2011.
8. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A: Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med, 77: 684-699, 2010.
9. Zhang H, Zhang D, Luan X, Xie G, Pan X: Inhibition of the signal transducers and activators of transcription (STAT) 3 signalling pathway by AG490 in laryngeal carcinoma cells. J Int Med Res, 38: 1673-1681, 2010.
10. Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, Yan B, Liang ZH, Zhu HF, Xu Y, Li B, Song CW, Liao SJ, Lei Z, Zhang GM, Feng ZH: Tumor Cell-released TLR4 ligands stimulate Gr- 1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol, 185: 2773-2782, 2010.
11. Filipowicz W, Grosshans H: The liver-specific microRNA miR-122: biology and therapeutic potential. Prog Drug Res, 67: 221-238, 2011.
12. Yanfeng Wu, Xinjun Liang, Yanyan Liu, Gong W, Liu JX, Wang XP, Zhuang ZQ, Guo Y, Shen HY: Antisense oligonucleotide targeting survivin inhibits growth by inducing apoptosis in human osteosarcoma cells MG-63. Neoplasma, 57: 501-506, 2010.
13. Tian L, Chen X, Sun Y, Liu M, Zhu D, Ren J: Growth suppression of human laryngeal squamous cell carcinoma by adenoviral-mediated interleukin-12. J Int Med Res, 38: 994- 1004, 2010.
14. Liu J, Tan L, Li H, Wang Q, Ji W: Suppression of S-phase kinase- associated protein 2 induces apoptosis and inhibits tumor growth in human laryngeal cancer. ORL J Otorhinolaryngol Relat Spec, 72: 205-214, 2010.
15. Hata K, Watanabe Y, Nakai H, Hata T, Hoshiai H: Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy. Anticancer Res, 31: 731-737, 2011.
16. Liang X, Da M, Zhuang Z, Wu W, Wu Z, Wu Y, Shen H: Effects of survivin on cell proliferation and apoptosis in MG-63 cells in vitro. Cell Biol Int, 33:119-124, 2009.
17. De Martino MC, van Koetsveld PM, Hofland LJ: Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology, 92 (Suppl 1): 28-34, 2010.
18. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA: The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta, 1803: 991-1002, 2010.
19. Dello Russo C, Lisi L, Tringali G, Navarra P: Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol, 78: 1242-1251, 2009.
20. Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F: The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer, 63: 264-271, 2011.
21. Memmott RM, Dennis PA: The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res, 16: 4-10, 2010.
22. Hashimoto I, Koizumi K, Tatematsu M, Minami T, Cho S, Takeno N, Nakashima A, Sakurai H, Saito S, Tsukada K, Saiki I: Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells. Eur J Cancer, 44: 1022-1029, 2008.
23. Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, Huang J, Saci A, Widlund HR, Fisher DE, Xiao Y, Rimm DL, Protopopov A, Wong KK, Chin L: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 459: 1085- 1090, 2009.
24. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A, Alvarez K, Chen G, Darnel AD, Aprikian AG, Saad F, Bismar TA, Squire JA: PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol, 218: 505-513, 2009.
25. Rai JS, Henley MJ, Ratan HL: Mammalian target of rapamycin: a new target in prostate cancer. Urol Oncol, 28: 134-138, 2010.
26. Guo Y, Liang X, Lu M, Weng T, Liu Y, Ye X: Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma. Hepatogastroenterology, 57: 913- 918, 2010.
27. Ji C, Yang B, Yang YL, He SH, Miao DS, He L, Bi ZG: Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene, 29: 6557-6568, 2010.
28. Sliva K, Schnierle BS: Selective gene silencing by viral delivery of short hairpin RNA. Virol J, 7: 248, 2010.
29. Lee WT, Tubbs RR, Teker AM, Scharpf J, Strome M, Wood B, Lorenz RR, Hunt J: Use of in situ hybridization to detect human papillomavirus in head and neck squamous cell carcinoma patients without a history of alcohol or tobacco use. Arch Pathol Lab Med, 132: 1653-1656, 2008.
30. García-Martínez JM, Wullschleger S, Preston G, Guichard S, Fleming S, Alessi DR, Duce SL: Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer, 104: 1116-1125, 2011.
31. Clegg NJ, Couto SS, Wongvipat J, Hieronymus H, Carver BS, Taylor BS, Ellwood-Yen K, Gerald WL, Sander C, Sawyers CL: MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One, 6: e17449, 2011.
32. Zhou H, Huang S: Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci, 12: 30-42, 2011.
33. Liu J, Stevens PD, Gao T: mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem, 286: 6510-6520, 2011.
34. Noske A, Lindenberg JL, Darb-Esfahani S, Weichert W, Buckendahl AC, Röske A, Sehouli J, Dietel M, Denkert C: Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep, 20: 1409-1417, 2008.
35. Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JI, Moon NM, Ko E, Noh WC: Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor- positive breast cancer. Breast Cancer Res Treat, 126: 93-99, 2011.
36. Mori K, Blanchard F, Charrier C, Battaglia S, Ando K, Duplomb L, Shultz LD, Redini F, Heymann D: Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk. Cancer Sci, 99: 2170-2176, 2008.
37. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res, 69: 7160-7164, 2009.
38. Garcia-Echeverria C: Blocking the mTOR pathway: a drug discovery perspective. Biochem Soc Trans, 39: 451-455, 2011.
39. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, Dumontet C, Cohen PA: mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci, 99: 1992-2003, 2008.
40. Dasanu CA, Clark BA 3rd, Alexandrescu DT: mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opin Investig Drugs, 18: 175-187, 2009.